Home > Insider Trading > Filing (0001209191-19-024839)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1269021	Portola Pharmaceuticals Inc	PTLA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1187333	Hollings Renton	C/O Portola Pharmaceuticals, Inc. 270 East Grand Ave. South San Francisco CA 94080		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-04-15	5,000	$9.00	14,000	No	4	M	Direct
Common Stock	Disposition	2019-04-15	4,600	$34.40	9,400	No	4	S	Direct
Common Stock	Disposition	2019-04-15	400	$35.07	9,000	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options (Right to Buy)	Disposition	2019-04-15	5,000	$0.00	5,000	$9.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
15,000		2020-04-27	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,826	Indirect	Held by The Renton Family Community Property Trust

Footnotes

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2019.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.9700 to $34.9650, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) - (3) to this Form 4.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.0000 to $35.1800, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) - (3) to this Form 4.
The option, representing a right to purchase a total of 20,000 shares, became exercisable monthly over a two year period beginning on May 29, 2010.